Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2659-2666

  Tricot, Guido ^a   Sawyer, Jeffrey R ^a   Jagannath, Sundar ^a   Raman Desikan, K ^a   Siegel, David ^a   Naucke, Sally ^a   Mattox, Sandy ^a   Bracy, Dwayne ^a   Munshi, Nikhil ^a   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; VINCRISTINE;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME DELETION 13; CYTOGENETICS; DIAGNOSTIC VALUE; DRUG MEGADOSE; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MYELOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 17144433568     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2659     Document Type: Article

References (46)

1. Barlogie B, Epstein J, Selvanayagam P, et al: Plasma cell myeloma - New biological insights and advances in therapy. Blood 73:865-879, 1989
2. Bataille R, Boccadoro M, Klein B, et al: C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737, 1992
3. Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell labeling index and B2-microglobulin predict survival independent of thymidine kinase and c-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993
4. Miguel JF, Garcia-Sanz M, Gonzalez MJ, et-al: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448-455, 1995
5. Ffrence M, Ffrench P, Remy F, et al: Plasma cell proliferation in monoclonal gammopathy: Relations with other biologic variables - Diagnostic and prognostic significance. Am J Med 98:61-66, 1995
6. Bataille R, Dune B, Grenier J, et al: Prognostic factors and staging in multiple myeloma. J Clin Oncol 4:80-87, 1986
7. Kyle R: Why better prognostic factors for multiple myeloma are needed. Blood 83:1713-1716, 1994
8. Fenaux P, Preudhomme C, Lay JL, et al: Cytogenetics and their prognostic value in de novo acute myeloid leukemia: A report on 283 cases. Br J Haematol 73:61-67, 1989
9. Seeker-Walker LM: Prognostic and biologic importance of chromosome findings in acute lymphoblastic leukemia. Cancer Genet Cytogenet 49:1-13, 1990
10. Dewald G, Kyle R, Hicks G, et al: The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66:380-386, 1985
11. Weh H, Gutensohn K, Selbach J, et al: Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 9:1269-1275, 1993
12. Sawyer J, Waldron J, Jagannath S, et al: Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82:41-49, 1995
13. Luc Lai J, Zandecki M, Mary J, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995
14. Drewinko B, Alexanian R, Boyer H, et al: The growth fraction of human myeloma cells. Blood 57:333-339, 1981
15. Tabernero D, San Miguel J, Garcia-Sanz R, et al: Incidence of chromosome numerical changes in multiple myeloma: Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149:153-161, 1996
16. Drach J, Schuster J, Nowotny H, et al: Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854-3859, 1995
17. Latreille J, Barlogie B, Johnson D, et al: Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59:43-46, 1982
18. Drach J, Angerler J, Schuster J, et al: Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cell from patients with monoclonal gammopathy of undetermined significance. Blood 86:3915-3921, 1995
19. Zandecki M, Obein V, Bemardi F, et al: Monoclonal gammopathy of undetermined significance: Chromosome changes are a common finding within bone marrow plasma cells. Br J Haematol 90:693-696, 1995
20. Gould J, Alexanian R, Goodacre A, et al: Plasma cell karyotype in multiple myeloma. Blood 71:453-456, 1988
21. Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256, 1995
22. Vesole DH, Tricot G, Jagannath S, et al: Autotransplants in multiple myeloma: What have we learned? Blood 88:838-847, 1996
23. Dao D, Sawyer J, Epstein J, et al: Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 8:1280-1285, 1994
24. Tian E, Barlogie B, Jagannath S, et al: Deletion of the Rb gene in plasma cells from human multiple myeloma patients does not correlate with decreased Rb-1 protein expression nor with up regulation of IL-6. Proc Am Assoc Cancer Res 36:564, 1995 (abstr 3362a)
25. Liu Y, Szekely L, Grander D, et al: Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci 90:8697-8701, 1993
26. Garcia-Marco J, Caldas C, Price C, et al: Frequent somatic deletion of the 13q12.3 locus encompassing BRCA2 in chronic lymphocytic leukemia. Blood 88:1568-1574, 1996
27. Kobayashi H, Saito H, Kitano K, et al: Overexpression of the PRAD1 oncogene in a patient with multiple myeloma. Acta Haematol 94:199-206, 1995
28. Bosch F, Jares P, Campo E, et al: PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: A highly specific marker of mantle cell lymphoma. Blood 84:2726-2727, 1994
29. Chesi M, Bergsagel P, Brents L, et al: Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88:674-681, 1996
30. Williams D, Harber J, Murphy S, et al: Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia. Blood 68:205-212, 1986
31. Rubin C, Le Beau M, Mick R, et al: Impact of chromosomal translocations on prognosis in childhood acute lymphoblastic leukemia. J Clin Oncol 9:2183-2192, 1991
32. Lane D: p53, guardian of the genome. Nature 358:15-16, 1993
33. Fukasawe K, Taesaeng Ch, Kuriyama R, et al: Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747, 1996
34. Eyfjord J, Thorlacius S, Steinarsdottir M, et al: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55:646-651, 1995
35. Portier M, Moles JP, Mazars G, et al: p53 and TAS gene mutations in multiple myeloma. Oncogene 7:2539-2543, 1992
36. Neri A, Baldini L, Trecca D, et al: p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128-135, 1993
37. Corradini P, Inghirami G, Astolfi M, et al: Inactivation of tumor suppressor gene, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758-767, 1994
38. Imamura J, Miyoshi I, Koeffler P: p53 in hematologic malignancies. Blood 84:2412-2421, 1994
39. Mazars G, Portier M, Zhang X, et al: Mutations of the p53 gene in human myeloma cell lines. Oncogene 7:1015-1018, 1991
40. Rouby S, Thomas A, Costin D, et al: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459, 1993
41. Dohner H, Fischer K, Bentz M, et al: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580-1589, 1995
42. Hecker S, Sauerbrey A, Volm M: p53 expression and poor prognosis in childhood acute lymphoblastic leukemia. Anticancer Res 14:2759-2762, 1994
43. Wattel E, Preudhomme C, Hecquet B, et al: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148-3157, 1994
44. Perego P, Giarola M, Righetti S, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562, 1996
45. Tricot G, Vesole D, Jagannath S, et al: Graft-versus-myeloma effect: Proof of principle. Blood 87:1196-1198, 1996
46. Verdonck L, Lokhorst H, Dekker A, et al: Graft-versus-myeloma effect in two cases. Lancet 347:800-801, 1996